Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04715763 · ClinicalTrials.gov registry record · Phase 2
INvestigating TELmisartin Study
A Phase 2 study, sponsored by University of Hawaii.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT04715763 is a Phase 2 study that was terminated before completion, run by University of Hawaii. The registered enrollment target is 24 participants.
The verdict
NCT04715763, a Phase 2 study, was terminated before completion, sponsored by University of Hawaii.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will enroll 40 inpatients hospitalized for COVID-19 at Queens' Medical Center. Participants will be randomized 1:1 to Telmisartan (80 mg) vs placebo to be administered orally once daily x 21 days.
Interventions
- DRUG Placebo
- DRUG Telmisartan Oral Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2022-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04715763
The ClinicalTrials.gov registry entry for NCT04715763 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Hawaii, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04715763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04715763 about?
NCT04715763 is a clinical study titled "INvestigating TELmisartin Study". This study will enroll 40 inpatients hospitalized for COVID-19 at Queens' Medical Center. Participants will be randomized 1:1 to Telmisartan (80 mg) vs placebo to be administered orally once daily x 21 days.
What is the current status of trial NCT04715763?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2021-09-01. Estimated completion is 2022-04-26.
What interventions are being tested in trial NCT04715763?
The interventions under investigation include: Placebo (DRUG), Telmisartan Oral Product (DRUG).
Who is sponsoring clinical trial NCT04715763?
This trial is sponsored by University of Hawaii, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.